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Enhancement of Hematopoietic Stem Cell
Repopulating Capacity and Self-Renewal
in the Absence of the Transcription Factor C/EBP
humans with AML (Zhang et al., 1997). C/EBP muta-
tions are found in a significant number of AML patients
with a normal karyotype (Pabst et al., 2001b; Gombart
et al., 2002; Preudhomme et al., 2002; Barjesteh van
Waalwijk van Doorn-Khosrovani et al., 2003). Patients
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with the t(8;21) AML1-ETO translocation do not harborand Daniel G. Tenen1,*
C/EBP mutations, but expression of C/EBP is down-1Harvard Institutes of Medicine
regulated (Pabst et al., 2001a). C/EBP is involved in the2Department of Cancer Immunology and AIDS
regulation of cell proliferation (McKnight, 2001). TheseDana-Farber Cancer Institute
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cell proliferation and leukemogenesis. However, these3Laboratory of Host Defenses
studies did not address the precise stage at which lossNational Institute of Allergy and Infectious Disease
of C/EBP affects myeloid differentiation, nor did theyBethesda, Maryland 20892
address the role of C/EBP in adult hematopoiesis and
in particular its function in stem cells.
Early hematopoietic precursors can be classified us-Summary
ing multicolor FACS according to their cell surface
marker expression pattern. Common myeloid progeni-The transcription factor C/EBP is required for granul-
tors (CMPs) differentiate into all myeloerythroid cells.opoiesis and frequently disrupted in human acute my-
CMPs can generate granulocyte/monocyte progenitorseloid leukemia (AML). Here, we show disruption of
(GMPs) and megakaryocyte/erythrocyte progenitors
C/EBP blocks the transition from the common my-
(MEPs) (Akashi et al., 2000). In these purified stem and
eloid to the granulocyte/monocyte progenitor but is
progenitor subsets, C/EBP is expressed at low levels
not required beyond this stage for terminal granulo-
in HSCs, and upregulated with development of CMPs
cyte maturation. C/EBP-deficient hematopoietic stem
and GMPs, but is shut down in MEPs or lymphoid cells
cells (HSCs) have increased expression of Bmi-1 and (Akashi et al., 2000; Traver et al., 2001; Miyamoto et
enhanced competitive repopulating activity. Bone al., 2002).
marrow in adult C/EBP-deficient mice was filled with Previous studies of C/EBP in myelopoiesis have
myeloblasts, similar to human AML, supporting the been done in vivo solely during fetal liver hematopoiesis
notion that disruption of C/EBP cooperates with due to the perinatal mortality of nonconditional knock-
other events in the development of leukemia. There- outs from hypoglycemia (Wang et al., 1995). The impor-
fore, C/EBP is not only essential for granulocyte de- tance of studying the role of transcription factors in
velopment but, in addition, is a regulator of hematopoi- adults has been emphasized by recent studies utilizing
etic stem cell activity. conditional targeting. At least two factors thought to
regulate stem cells based on nonconditional knockout
Introduction models, AML1 and SCL, have been shown to have a
muchmore limited role in adult hematopoiesis (Ichikawa
et al., 2002; Mikkola et al., 2003; Hall et al., 2003). There-Myeloid cells develop from HSCs through intermediate
fore, several questions regarding the role of C/EBP inmyeloid progenitors, which normally differentiate further
hematopoiesis remain unclear. First, will disruption ofinto granulocytes and monocytes, and their importance
C/EBP in adult mice result in accumulation of blastsis emphasized by the characteristic accumulation of
blocked in differentiation? Second, at what stage isbone marrow blasts in AML. Several transcription fac-
granulopoiesis blocked in C/EBP/ mice? Third, be-tors are involved in the differentiation fromHSC to termi-
causeC/EBP is expressed inHSCs, is C/EBP involvednally mature granulocytes and monocytes (Tenen et al.,
in self-renewal or lineage commitment of stem cells?1997; Tenen, 2003). The transcription factor C/EBP is
Fourth, will accumulation of such blasts result in devel-a key factor for granulopoiesis (Radomska et al., 1998).
opment of AML?C/EBP is expressed in myeloid cells and regulates
We analyzed hematopoietic development in bothmany myeloid genes (Iwama et al., 1998; Tenen et al.,
C/EBP/ fetal liver and bone marrow from conditional1997). In C/EBP, nonconditional knockouts have a
C/EBP/ mice. Here, we demonstrate that disruptionblock in granulocyte differentiation in fetal liver and new-
of the C/EBP gene blocks the transition from CMP toborns. Immature myeloid cells accumulate in fetal liver
GMP and results in accumulation of 30% blasts in theand peripheral blood, similar to what is observed in
adult bone marrow, resembling human AML. Further-
more, C/EBP/ HSCs express increased levels of the
*Correspondence: dtenen@bidmc.harvard.edu polycomb gene Bmi-1, which can enhance HSC self-
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renewal (Iwama et al., 2004 [this issue of Immunity]) and5Present address: The Blood Center of SE Wisconsin, Milwaukee,
demonstrate a competitive advantage over wild-typeWI 53233.
(wt) HSC. These results indicate that C/EBP normally6Present address: Millennium Pharmaceuticals, Inc., Cambridge,
MA 02139. serves to limit HSC self-renewal.
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Figure 1. Generation of a Conditional C/EBP Knockout Mouse Lines
(A) Top, the genomic C/EBP locus; middle, after targeted insertion of loxP sequences flanking the single C/EBP exon and neomycin
resistance gene (neoR); bottom, genomic structure after C/EBP and neoR are deleted by Cre-mediated gene excision. Double-headed arrows,
probe used in assessment of excision efficiency by Southern blot analysis. B, BamHI restriction enzyme site. Expected sizes of bands detected
on Southern blots are indicated for wt, floxed, and targeted alleles. Single-headed arrows, primers used in PCR reactions for genotyping the
C/EBPF/F mice.
(B) The C/EBP gene was efficiently excised from bone marrow, spleen, and thymus in C/EBP/ mice. Southern blot analysis of genomic
DNA from poly I:C treated C/EBPF/F and Mx1-Cre x C/EBPF/F (C/EBP/) mouse bone marrow, spleen, and thymus were digested with
BamHI and hybridized with the probe shown in Figure 1A. Arrows on the right indicate the targeted allele (10.9 kb) and excised allele (4.7 kb).
(C) C/EBP protein expression is not detectable in the bone marrow of C/EBP/ mice. Western blot analysis of whole-cell lysates of adult
liver and total bone marrow cells from two C/EBPF/F and C/EBP/ mice.
Results I:C intraperitoneally once 2 days after birth as described
(Kuhn et al., 1995). Excision of the floxed gene is report-
edly 35% of bone marrow cells 1 week after poly I:CGeneration of Mice with Conditional Disruption
of the C/EBP Gene
Nonconditional C/EBP/mice die perinatally of hypo-
Table 1. Peripheral Blood Differential Counts of C/EBPF/F
glycemia (Wang et al., 1995). In order to analyze the and C/EBP/ Mice
role of C/EBP in the adult, we generated conditional
C/EBPF/F C/EBP/C/EBP knockouts (Figure 1A). There were no notable
abnormalities in the hematopoietic system among RBC (M/l) 8.4  1.5 9.2  0.5
Hemoglobin (g/dl) 14.0  1.3 14.6  0.6C/EBP/, C/EBPF/, and C/EBPF/F mice (Table 1,
HCT (%) 42.3  2.9 44.3  2.0Supplemental Figure S1 available online at http://www.
Platelet x (K/l) 509.57  295.2 980.4  544.8immunity.com/cgi/content/full/21/6/853/DC1/, and
Total WBC (K/l) 3.9  0.6 4.4  1.3
data not shown), indicating that the floxedC/EBP allele Lymphocyte (%) 78.6  1.4 99.7  0.5
functions like the wt gene. We bred C/EBPF/F mice with Neutrophils (%) 16.8  4.2 0
Mx1-Cre transgenic mice, in which Cre can be induced Monocyte (%) 2.2  1.4 0.3  0.5
Eosinophils (%) 2.4  1.4 0with interferons or synthetic double-stranded RNA poly-
inosinic-polycytidylic acid (poly I:C) (Kuhn et al., 1995). RBC, Hgb, HCT, platelet counts, and total WBC were determined
Studies have demonstrated near complete recombina- with an automated cell counter (Hemovet) at 3 weeks of age after
treatment with poly I:C 2 days after birth. WBC differentials weretion of floxed alleles in bone marrow by using Mx1-Cre
determined by morphology of 200–300 cells stained with Wright-strain, including early progenitors (Radtke et al., 1999;
Giemsa. Shown are the numbers from ten mice with each geno-Higuchi et al., 2002).
type  standard deviation.
Mx1-Cre  C/EBPF/F mice were injected with poly
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Table 2. Analysis of Differential Counts, Hematopoietic Stem Cell and Progenitor Numbers in Nonconditional Fetal Liver, and Conditional
Bone Marrow Derived from Mice with Disruption of C/EBP
Genotype Blast Promyelocyte Myelocyte Neutro Mono Eosinophil Erythroblast Lymphoid
aC/EBPF/F 1.0  0.3 1.6  0.6 9.8  5.4 37.0  2.8 1.7  1.9 2.6  2.0 36.4  5.5 12.6  7.1
C/EBP/ 32.7  4.8 1.0  0.6 1.1  0.3 1.4  3.4 0.2  0.1 0 41.4  6.0 21.2  4.0
HSC CMP GMP MEP
bFL C/EBP/ 0.25%  0.043% 0.62%  0.015% 0.49%  0.11% 1.80%  0.11%
FL C/EBP/ 0.30%  0.068% 0.32%  0.017%* 0.0%  0.03%* 3.80%  0.69%*
rBM C/EBP/ 0.09% 1.04% 0.72% 1.18%
rBM C/EBP/ 2.89%* 5.5%* 0.04%* 4.78%*
aSix mice were evaluated for each genotype 3–4 weeks after induction of deletion with poly I:C. Shown are the percentages of total bone
marrow cells as assessed by Wright-Giemsa staining  SD.
bFL refers to embryonic day 14.5 fetal liver from C/EBP/ and nonconditional C/EBP/ knockout mice. rBM refers to recipient bone
marrow from C/EBP/ and C/EBP/ fetal liver transplanted mice. Shown are the percentages  SD of total fetal liver hematopoietic cells
(FL) or total bone marrow cells (rBM) derived from 6 (FL) and 3 (rBM) mice in each category, respectively. An asterisk (*) indicates p 	 0.05
compared to C/EBP wt.
and 85% at 2 weeks (Higuchi et al., 2002). Therefore, in adult C/EBP/ mice are compatible with that seen in
C/EBP/ fetal liver cells. The lack of granulopoiesis inwe analyzed mice 3 to 4.5 weeks after injection. As
shown in Figure 1B, C/EBP gene deletion efficiency is all hematopoietic organsdemonstrates that loss of gran-
ulocytes in the peripheral blood of C/EBP/ mice ishigher than 95% in all hematopoietic tissues tested.
C/EBP protein in Mx1-Cre  C/EBPF/F mice was de- not due to lack of migration from the bone marrow to
spleen or peripheral blood.creased to undetectable levels in bone marrow after
excision (Figure 1C). Therefore, Mx1-Cre  C/EBPF/F
mice represent an excellent model to study the role of The Block in Differentiation Resulting from Disruption
C/EBP during adult hematopoietic development. We of the C/EBP Gene in Mice Occurs at the Transition
shall refer to poly I:C treated Mx1-Cre  C/EBPF/F from CMP to GMP in Fetal Liver
mice as C/EBP/ for the sake of brevity, with the real- and Adult Hematopoiesis
ization that a small fraction (	5%) of C/EBP/ hemato- In order to locate the stage of differentiation block, we
poietic cells have likely not deleted the C/EBP gene. characterized the change in the distribution of myeloid
progenitors by using multiple cell surface markers
(Akashi et al., 2000). As shown in Figure 2, GMPs wereDisruption of the C/EBP Gene in Adult Mice
Selectively Blocks Granulocytic Development almost completely absent in C/EBP/ fetal liver hema-
topoiesis, and relative increases inMEPswere observedAs granulopoiesis is selectively blocked in the fetal and
newborn liver in C/EBP nonconditional knockout mice (Figure 2A and Table 2). This phenotype was identical
in adult bone marrow lacking C/EBP (Supplemental(Zhang et al., 1997), we tested whether we would see
the same phenotype in C/EBP/ adult bone marrow Figure S1).
The lack of GMPs could either represent a true ab-cells. As shown in Table 1, the number of erythroid cells
in peripheral blood was unaffected in C/EBP/ mice sence of this population in the absence of C/EBP or
else an artifact as a result of dysregulation of one of theas compared to poly I:C treated C/EBPF/F controls. Pe-
ripheral bloodplateletswere elevated, aswas the case in markers used to define this population. In order to verify
that the phenotypic CMP isolated from C/EBP/miceC/EBP/ fetal livers (Zhang et al., 1997); this difference
was not statistically significant. Although the total white function as CMP, we performed colony-forming unit
(CFU) assays. CMPs were isolated by FACS and single-blood cell count was similar, no mature granulocytes
were observed in C/EBP/ mice, and the percentage cell CFU assays performed in methycellulose. CMPs
purified from C/EBP/ fetal liver cells and C/EBP/of lymphocytes was slightly increased. We observed no
accumulation of immaturemyeloid cells in the peripheral bone marrow exhibited clonogenicity similar to that of
wt and hadno significant change in thenumber ofmixed,blood. In the bone marrow, C/EBP/ mice displayed
a significant differentiation block in myeloid maturation. erythroid, megakaryocytic and mixed erythroid/mega-
karyocytic colonies (Figure 2B and Supplemental FigureMyelocytes, neutrophils, monocytes, and eosinophils
were rarely seen in theC/EBP/bonemarrow,whereas S1), demonstrating their normal erythroid and mega-
karyocytic potentials. However, no mature granulo-immature myeloblasts were increased up to 32% (Table
2), which is one of the diagnostic criteria for humanAML. cyte-macrophage (GM), macrophage (M), or granulo-
cytic (G) colonies could be generated from C/EBP/However, in C/EBP/ bone marrow, the percentages
of erythroblasts were normal (Table 2). or C/EBP/CMPs. Instead, C/EBP/ andC/EBP/
CMPs gave rise to an equivalent number of blastic colo-Consistent with these morphological observations,
C/EBP/ mice displayed a dramatic loss of Gr-1 nies, which did not display myeloid maturation (Figure
2B and Supplemental Figure S1). The myeloid compo-Mac-1 neutrophils/monocytes on FACS analyses in
bone marrow (Supplemental Figure S1), spleen, and pe- nent in C/EBP/ or C/EBP/ CMP-derived mix colo-
nies also displayedblastic immaturemorphology (Figureripheral blood (Supplemental Table S1). T and B cells
remained normal (Supplemental Table S1). These data 2B and data not shown). Therefore, CMP derived from
Immunity
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Figure 2. Disruption of the C/EBP Gene in Fetal Liver Blocks the Transition from CMP to GMP
LinIL-7RSca-1c-Kit cells isolated by multicolor flow cytometry on the left (A) were further analyzed with CD34 and Fc
RII/III on the right
(B). A similar pattern was observed in 10 different C/EBP/ mice. Numbers in the figures indicate the percentage of total fetal liver
hematopoietic cells.
(B) CMPs derived from C/EBP/ fetal livers differentiated into multiple lineages in vitro in CFU assays. 96 individual CMPs from C/EBP/
wt and C/EBP/micewere sorted and distributed one cell per well into 96-well plates containingmethylcellulose. The bar graph demonstrates
the numbers of each type of colony observed in the plate. Shown to the right of each bar graph is a Wright-Giemsa stained CFU-mix colony,
showing mature granulocytic and monocytic cells derived from C/EBP/ fetal livers not observed in those derived from C/EBP/ embryos.
Mix colonies from C/EBP/ CMP are defined as those including normal appearing megakaryocytes and erythroid cells and immature
myeloid blasts.
C/EBP deficient fetal liver and adult bone marrow do in vitro. The distribution of GM, G, and M colonies de-
rived from Cre (C/EBP/) GMP was similar to that ofpossess multilineage differentiation potential but are in-
capable of differentiating to formmyeloid CFU or granu- Cre (C/EBPF/F) GMP (Figure 3B), and the cells in these
colonies were just as differentiated (Figures 3C and 3D).locytic cells. In conclusion, disruption of the C/EBP
gene blocks the transition from CMP to GMP in vivo Therefore, C/EBP is required for differentiation of CMP
to GMP. However, once GMP have been produced,and the granulocytic maturation of CMPs in vitro.
C/EBP is no longer required for maturation to more
differentiated myeloid cells (granulocytes and mono-C/EBP Is Not Required for Terminal Granulocytic
cytes), indicating a role early, but not late, in granulo-Maturation beyond the GMP Stage
cytic differentiation.The experiments described above demonstrate that
C/EBP is required for the transition from CMP to GMP
but did not address whether continued expression of C/EBP Deficiency Leads to Augmentation
of Hematopoietic Stem Cell FunctionC/EBP beyond the GMP stage is required for granulo-
cytic maturation. We isolated GMP from C/EBPF/F mice We have shown that the C/EBP/ fetal liver hemato-
poietic cells that reconstituted lethally irradiated recipi-and transduced them with a retrovirus expressing Cre
recombinase and EGFP. Polymerase chain reaction ents could differentiate into mature T and B cells, but
not mature granulocytes (Zhang et al., 1997). However,(PCR) analysis of genomic DNA revealed excision only in
the EGFP (Cre) population (Figure 3A), demonstrating these experiments were not definitive because they uti-
lized total fetal liver cells and not purified progenitorthat the absence or presence EGFP was an accurate
marker of floxed or excised alleles, respectively. We populations as donors, and the recipient mice did not
survive beyond 8 weeks. Therefore, in order to deter-then asked whether deletion of C/EBP in the GMP
population would affect myeloid colony formation mine whether the specific differentiation block from
C/EBP/ Stem Cell Function
857
Figure 3. C/EBP Is Not Required after the
GMP Stage of Myeloid Differentiation
(A) Complete excision of both C/EBPF/F al-
leles after retroviral transduction of Cre re-
combinase. GMP isolated from C/EBPF/F
mice were transduced with Cre-IRES-EGFP
retrovirus, sorted as EGFP (Cre, lanes 1
and 4) and EGFP (Cre, lanes 2 and 5) and
then assessed for presence of the C/EBPF
(floxed, lanes 1 and 2) or C/EBP (excised,
lanes 4 and 5) allele. Lane 3, DNA size mark-
ers (M).
(B) Myeloid colony formation in unexcised
(Cre) and excised (Cre) C/EBPF/F GMP.
The chart indicates the number of CFU-GM,
CFU-G, and CFU-M per 100 GMP plated.
(C and D) Morphology of cells derived from
Cre (C) and Cre (D) CFU-GM; note the pres-
ence of both macrophages (Mac) and granu-
locytes (G).
CMP to GMP stages in C/EBP-deficient mice is cell pression of the homeobox gene HoxB4 has been dem-
onstrated to lead to an expansion in HSC (Sauvageauautonomous, we transplanted 200 total fetal liver HSCs
consisting of various ratios of Ly5.2 C/EBP/ or et al., 1995), we measured HoxB4 RNA levels through
quantitative real-time PCR. Again, no differences couldC/EBP/ and Ly5.1 C/EBP/ HSCs into lethally
irradiated Ly5.1 C57BL/6 congenic mice. Surprisingly, be detected among HSC derived from C/EBP/,
C/EBP/, and C/EBP/ mice (Figure 4C, bottom).C/EBP/ HSCs were able to out compete C/EBP/
HSCs. As shown in Figure 4A, left, the number of Ly5.2 A final candidate gene that we investigated was the
polycomb gene Bmi-1. Loss of Bmi-1 leads to a pro-(donor) cells increased steadily over time, even when
four times as many wt HSCs were utilized. All of the found defect in HSC self-renewal (Park et al., 2003; Les-
sard and Sauvageau, 2003). Furthermore, increased ex-Ly5.2 cells in the recipients receiving C/EBP/ HSCs
were CD3or B220 lymphoid cells, and no Ly5.2 gran- pression of Bmi-1 leads to increased self-renewal and
marked enhancement of HSC repopulating activityulocytes (Gr-1/Mac-1) could be detected (data not
shown). Most of the HSCs in those recipients with a in vivo (Iwama et al, 2004 [this issue of Immunity]). In
contrast to what we observed with HoxB4, Bmi-1 RNAhigh degree of peripheral blood chimerismwere derived
from C/EBP/ HSC, as assessed by both phenotypic was increased an average of 3.5-fold in HSC derived
from C/EBP/ mice compared to those purified fromanalysis (Figure 4B) or the ability to repopulate the hema-
topoietic system in secondary (Figure 4A, right) and ter- C/EBP/ (Figure 4C, top). Therefore, the enhancement
of HSC repopulating activity in C/EBP/ HSC wastiary transplantation experiments (data not shown).
Analysis of the bone marrow in the primary recipients accompanied by a significant increase in expression of
Bmi-1.also confirmed that C/EBP/ fetal liver HSC conferred
the same distinct block in differentiation at the CMP to We also asked whether HSC derived from adult bone
marrow deficient in C/EBP could confer the same phe-GMP stage and that a proportional number of HSCs,
CMPs, and MEPs, but not GMPs, were derived from the notype after transplantation into congenic recipient
mice by transplanting mixtures of Ly5.2 Mx1-Cre Ly5.2C/EBP/ fetal liver HSC (Figure 4B). In addition,
B220 B cells, but not Mac-1 myeloid cells, were de- C/EBPF/F and Ly5.1 C/EBP/ bone marrow cells,
establishing chimerism after transplantation, and thenrived from C/EBP/ fetal liver HSCs. Therefore, loss of
C/EBP appeared to augment competitive repopulation inducing deletion of the C/EBP gene by administration
of poly I:C 2.5 months after transplantation. Southernactivity of HSCs.
We sought to determine the mechanism through blot analysis demonstrated thatwe could achieve90%
deletion of C/EBP after multiple injections of poly I:Cwhich loss ofC/EBP led to this effect. C/EBP hasbeen
demonstrated to inhibit the cell cycle through multiple in 3-month-old Mx1-Cre  C/EBPF/F mice (data not
shown), similar to that after newborn injection (Figuremechanisms (McKnight, 2001). However, BrdU labeling
experiments failed to demonstrate any differences in 1). As shown in Figure 5A, analysis of the bone marrow
of these mice revealed that a block at the CMP to GMPcell cycle status between HSC derived from C/EBP/,
C/EBP/, and C/EBP/mice (data not shown), mak- transition could be detected in bone marrow precursors
arising from Ly5.2 donor C/EBP/ bone marrow cellsing effects on cell cycle an unlikely reason for the
enhanced HSC self-renewal. Because increased ex- after long term transplantation. Furthermore, analysis of
Immunity
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Figure 4. C/EBP/ Fetal Liver Hematopoietic Stem Cells Have a Competitive Advantage over Wt
(A) Left, fetal liver HSCs consisting of Ly5.2 C/EBP/ and Ly5.1 C/EBP/ at ratios of 1:1 and 1:4, or Ly5.2 C/EBP/ and Ly5.1
C/EBP/ at a ratio of 1:1 were transplanted into lethally irradiated Ly5.1 congenic recipients, and the percentage of donor Ly5.2 cells in
peripheral blood is plotted as a function of time after transplantation. A total of 200 fetal liver HSCs were transplanted into each recipient.
Solid lines denote Ly5.2 C/EBP/: Ly5.1 C/EBP/ HSCs at a ratio of 1:1 (100 Ly5.2 C/EBP/ plus 100 Ly5.1 C/EBP/ HSCs as
donors) and the dashed lines 1:4. Dotted lines denote Ly5.2 C/EBP/: Ly5.1 C/EBP/ HSC at a ratio of 1:1 (100 Ly5.2 C/EBP/ plus
100 Ly5.1 C/EBP/ HSCs as donors). The cross indicates unexpected death of one of the recipients. #6, #7, and #9 refer to recipient mice
shown in Figure 4B. Right, secondary transplantation. 2 106 total bone marrow cells frommouse #7 (Ly5.2 C/EBP/ and Ly5.1 C/EBP/
cells) and #9 (Ly5.2 C/EBP/ and Ly5.1 C/EBP/ cells) were transplanted into Ly5.1 C/EBP/ recipients. The graph demonstrates
the percentage of Ly5.2 peripheral blood cells in three different recipient mice for donor #7 and five for donor #9.
(B) Relative numbers of HSC, progenitors, and B220 B cells and Mac-1hi myeloid cells in bone marrow and spleen of recipient mice #6 and
#7 from primary transplantation experiments (Figure 4A, left). All populations are mainly derived from C/EBP/ Ly5.2 donor cells with the
exception of GMP and Mac-1hi cells representing granulocytes and their precursors.
(C) Bmi-1 RNA is increased in C/EBP/ HSC. Bmi-1 (top) and HoxB4 (bottom) RNA was determined by quantitative real-time PCR and
shown as percentage of 18S RNA. Data for this figure are derived from two embryonic day 15.5 C/EBP/ and C/EBP/ fetal livers,
respectively. Similar data was obtained by using pooled RNA derived from four knockout and heterozygote mice. Bmi-1 RNA was increased
3.5-fold in C/EBP/ versus C/EBP/ HSCs.
bone marrow and peripheral blood of long-term recipi- injection of poly I:C at birth, C/EBP/ animals demon-
strated a phenotype with some characteristics resem-ent mice indicated that C/EBP/ bone marrow could
contribute to productionof HSC,CMP,MEP, andperiph- bling AML, including no mature peripheral blood granu-
locytes (Table 1 and Supplemental Table S1) and theeral blood B220 B cells, but not GMP or peripheral
bloodMac-1granulocytic cells (data not shown). These presence of 30% immature myeloid cells in the bone
marrow (Figure 5B and Table 2), but without anemia orresults demonstrate that persistent block in granulocytic
differentiation at the CMP to GMP transition is indeed thrombocytopenia (Table 1). Most of these blasts have
phenotypic markers of CMP (Supplemental Figure S1).a cell autologous effect.
We therefore asked the questionofwhether this hemato-
poietic state would be transient, whether it would per-C/EBPDeficiency in Adult Mice Leads to Persistence
of Immature Myeloid Blasts without the Development sist, or alternatively whether it would progress to include
other characteristics of leukemia. We observed that theof Malignant AML
Because disruption of C/EBP leads to a block in my- animals rarely survived beyond 4 to 5 weeks of age due
to sepsis as a result of granulocytopenia (Table 1). Toeloid maturation, increased stem cell repopulating func-
tion, and accumulation of immature myeloid blasts in date, 8 C/EBP/ mice have been followed for 2 to 5
months. One animal appeared to succumb from dis-the bone marrow, we asked whether loss of C/EBP
would lead to development of AML. Three weeks after seminated intravascular coagulation and likely had sep-
C/EBP/ Stem Cell Function
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Figure 5. Excess Blasts Persist in C/EBP/ Bone Marrow without Transition to Myeloid Leukemia
(A) The differentiation block in C/EBP deficient adult bone marrow is cell autonomous. Different mixtures derived from Ly5.2 C/EBPF/F (#23
Cre) or Ly5.2 Mx1-Cre  C/EBP F/F (#35 and #49) and Ly5.1 C/EBP/ bone marrow cells (total 4  105 cells) were used as donor cells
and transplanted into lethally irradiated Ly5.1 congenic recipients. 1:4, 1:8, and 1:1 indicate the ratios of Ly5.2 to Ly5.1 donor cells. 2.5
months after transplantation, poly I:C was administered and the mice were analyzed 6 months later, a total of 8.5 months after transplantation.
The figure demonstrates donor Ly5.2 HSCs, CMPs, GMPs, or MEPs as a percentage of the total of each population. There were 1% Ly5.2
GMPs in Cre mice.
(B) Wright-Giemsa staining of bone marrow from 6-week-old Mx1-Cre  C/EBPF/F (left) and C/EBP/ mice (right) after poly I:C induction
2 days after birth. Note mature neutrophils in the left (arrow) and their absence in the right and the presence of myeloid blasts (right, arrow).
Similar results were observed in over 20 C/EBP/ mice. Poly I:C-treated wt and Mx1-Cre mouse bone marrow demonstrated morphology
similar to that shown on the left.
sis. Another animal was necropsied shortly after death progress to a true myeloid leukemia. The persistence
of excess C/EBP/ blasts in the bone marrow of miceand had an elevated peripheral blast count (60%), but
based on peripheral blood smear did not appear anemic lacking C/EBP supports the notion that loss of C/EBP
leads to an increase in HSC self-renewal compared toor thrombocytopenic, and a third animal had 8% imma-
ture blasts in the peripheral blood. The remaining five that of wt HSC.
mice demonstrated a persistence of the same hemato-
logic picture seen at 3 weeks without development of Discussion
other characteristics of leukemia. This statewas charac-
terized by excess blasts in the bone marrow and ab- We previously described that granulocytic differentia-
tion is blocked along with an accumulation of immaturesence of peripheral blood granulocytes, but normal he-
matocrit, hemoglobin, and platelet count, and lack of myeloid blasts in nonconditional C/EBP/ fetal liver
hematopoiesis (Zhang et al., 1997). To study the role ofmalignant infiltration of other tissues. Furthermore, we
have not detected progression to leukemia after long- C/EBP during adult hematopoiesis, we utilized the
Mx1-Cre strain of mice. We, and others, (Higuchi et al.,term (9months)monitoring of chimericmicegenerated
by transplantation of adult bone marrow cells lacking 2002) have not observed abnormalities in myelopoiesis
in Mx1-Cre mice with the dosage of poly I:C utilized inC/EBP (Figure 5A). In summary, at least over this time
period, this AML-like state consisting of an excess num- these studies. In addition, the effects observed in double
Mx1-Cre  C/EBPF/F mice induced with poly I:C areber of myeloid blasts persists but does not commonly
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similar in many respects to those observed in the fetal sion of Bmi-1. In the accompanying manuscript, Iwama
et al. (2004) demonstrate that increased expression ofliver of nonconditional C/EBP/ mice and are trans-
Bmi-1 in HSC leads to marked enhancement of HSCplantable (Figure 5). Therefore, we believe that hemat-
repopulating activity in vivo, a phenotype remarkablyopoietic effects are specifically due to loss of the
similar to what we observe in C/EBP/ HSC. A some-C/EBP gene.
what surprising finding was that we could not detect
differences in cell cycle status of HSC derived fromC/EBP Function in Myeloid Progenitors
C/EBP/ mice, but Iwama et al. (2004) also reportedIn the present study, by using loss of function studies,
that disruption of Bmi-1 did not affect HSC cell cycle,we have demonstrated that C/EBP is not required for
supporting the idea that upregulation of Bmi-1 could becommitment of HSCs to CMPs but has a very specific
the basis of augmented repopulating ability of C/EBP/role in the transition of the CMP to the GMP stage. In
HSC. Further experiments testing HSC derived fromaddition, the enforced expression of C/EBP in CLPs
mice with targeted disruption of both C/EBP andinduces granulocyte/monocyte development, indicating
Bmi-1 will be required to confirm this hypothesis. Strik-that C/EBP can activate silenced myeloid programs to
ingly, Bmi-1 expression in HSC and progenitors (Iwamaconvert CLPs into GMPs (H.I. and K.A., unpublished
et al., 2004) is reciprocal to that of C/EBP. Bmi-1 isdata). These studies establish that C/EBP is an instruc-
expressed in HSC and multipotential progenitors, main-tive and indispensable regulator of GMP commitment.
tained in lymphocytes, and markedly downregulated inHowever, once myeloid maturation has reached the
Gr-1myeloid cells, whereas the expression of C/EBPGMPstage, C/EBP is no longer required (Figure 3). This
is upregulated as HSCs mature to GMPs, expressed atobservation is consistent with the findings that upon
highest levels inGr-1granulocytes (Pabst et al., 2001a),induction of myeloid differentiation, C/EBP DNA bind-
and not expressed in either early progenitors or matureing activity is rapidly replaced by that of other C/EBP
cells from the lymphoid lineage (Akashi et al., 2000;family members, such as C/EBP and/or C/EBP (H.S.
Miyamoto et al., 2002). Therefore, future experimentsRadomska and D.G.T., unpublished data); that C/EBP
will be directed at determining whether Bmi-1 is a directcan rescue the granulocytic defect in C/EBP/ mice
target of C/EBP and that one of the normal functions(Jones et al., 2002); and that C/EBP and C/EBP can
of C/EBP is to inhibit HSC self-renewal in myeloid pro-induce myeloid maturation in cell line models (Park et
genitors by downregulating Bmi-1.al., 1999; Nakajima and Ihle, 2001; Duprez et al., 2003)
Furthermore, the role of C/EBP in HSCs appears toand in vivo (Truong et al., 2003). An alternative is that
be quite distinct from its function to induce CMPs toonce GMP develop, further myeloid maturation can pro-
differentiate into GMPs. In HSC, C/EBP plays a roleceed in the absence of C/EBP due to the actions of
in self-renewal and repopulating activity, whereas, incytokines such as IL-3 and GM-CSF (Zhang et al., 1998,
contrast, in the transition fromCMPs to GMPs, the func-2002). Further experiments utilizing compound C/EBP
tion of C/EBP appears to be to promote myeloid differ-family member knockouts will help distinguish these
entiation. As a transcription factor, C/EBP has a crucialpossibilities. Interestingly, GMP lacking PU.1 are unable
role in regulating the balance between cell proliferationto differentiate under the identical conditions (H.I., C.
and differentiation (McKnight, 2001; Johansen et al.,Somoza, H. Shigematsu, E.A. Duprez, J.I.-A., S.-i. Mi-
2001; Porse et al., 2001). Taken together, these resultszuno, K. Geary, P.Z., T. Dayaram, M. Fenyus, S. Chan,
suggest that loss of C/EBP leads to not only a block inC.S.H., R. Murray, D.G.T., and K.A., unpublished data),
myeloid cell differentiation but may selectively promotesuggesting thatwhatever synergy (Petrovick et al., 1998)
proliferation. Whereas our data suggests that loss of
or antagonism (Reddy et al., 2002; Dahl et al., 2003)
C/EBP does not measurably affect the cell cycle of
these two transcription factors demonstrate in myeloid
HSC, a recent report demonstrated increased prolifera-
differentiation PU.1, and not C/EBP, is required after tionof C/EBP/progenitors in vitro (Heath et al., 2004).
the GMP stage. Therefore, it is possible that these discrete functions of
C/EBP in HSCs compared to progenitors may be due
An Additional Function of C/EBP to differences in effects on cell cycle.
in Hematopoietic Stem Cells Loss in peripheral blood granulocytes and increase
Surprisingly, loss of C/EBP led to an effect on stem in blasts in the bone marrow persisted for at least 5
cell function. CEBP is expressed at low levels in HSCs months in C/EBP/mice that were able to avoid infec-
and is upregulated in CMPs and GMPs (Akashi et al., tions and survive for this period of time. This is quite
2000; Traver et al., 2001). By using more precise real- distinct from our results in Mx1-Cre  PU.1F/F animals,
time RT-PCR methods, we have found that C/EBP is in which PU.1-deficient hematopoiesis could be main-
expressed at about 0.1% of 18S ribosomal RNA levels tained for only a few weeks (H.I., C. Somoza, H. Shige-
in HSC, increases 2-fold during the transition from HSC matsu, E.A. Duprez, J.I.-A., S.-i. Mizuno, K. Geary, P.Z.,
to CMP, subsequently increases 10-fold as CMPs differ- T. Dayaram, M. Fenyus, S. Chan, C.S.H., R. Murray,
entiate to GMP, and decreases 10-fold as CMPs differ- D.G.T., and K.A., unpublished data). Assuming deletion
entiate into MEPs (P.Z. and E.L., unpublished data). Our of C/EBP and PU.1 are equally efficient in HSC in the
results demonstrate the importance of the transcription two strains, these results suggest that loss of C/EBP
factor C/EBP in HSCs; relatively very low levels of ex- in the stem cell provides a selective advantage over wt
pression are important in HSC functions such as com- HSC, whereas loss of PU.1 results in defective HSC
petitive reconstitution activity. Furthermore, we suggest function, compatible with previous reports utilizing pro-
a possible mechanism for the enhanced HSC self- genitor populations (Scott et al., 1997). PU.1-deficient
fetal liver also exhibited a differentiation block fromrenewal observed in C/EBP/mice: increased expres-
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C/EBP genomic fragment and subsequently ligated into theHSCs to CMPs as well as CLPs (H.I., C. Somoza, H.
pPNTloxP targeting vector backbone (Kimura et al., 2002) directlyShigematsu, E.A. Duprez, J.I.-A., S.-i. Mizuno, K. Geary,
after the loxP site. The targeting plasmid was linearized with NotIP.Z., T. Dayaram,M. Fenyus, S. Chan, C.S.H., R. Murray,
and introduced into TC1ES. GenomicDNAwasdigestedwithBamHI
D.G.T., and K.A., unpublished data). Thus, although both and NotI and hybridized to an 875 bp Pst I-Xba I fragment derived
C/EBP and PU.1 are critical for differentiation of my- from the 7 kb EcoRI 5 C/EBP genomic fragment described above.
The targeted allele generated a 10.9 kb band, whereas the wt alleleeloid cells at their progenitor stages, the loss of C/EBP
generated a 5 kb band. Selected ES cell clones were injected intoand PU.1 in HSCs resulted in opposite effects on their
C57BL/6 blastocysts, implanted into (CBA  C57BL/6)F1 fosterrepopulating activity and showed that they both play
mothers, and propagated as described (Yamanaka et al., 1997).distinct roles in HSCs and CMPs. One possible mecha-
nism leading to the marked enhancement in C/EBP/ Genotyping Mx1-Cre and C/EBPF/ Mice
and not PU.1/ HSC is due to selective upregulation Mx1-Cre mice (kindly provided by Klaus Rajewsky) (Kuhn et al.,
of Bmi-1. This hypothesis is strengthened by the finding 1995) were genotyped by PCR yielding a 300 bp product with prim-
ers 5-ATGTTCAATTTACTGACCG-3 (sense primer) and 5-CGCthat whereas Bmi-1 is upregulated in C/EBP/ HSC
CGCATAACCAGTGAAAC-3 (antisense primer). C/EBPF/ mice(Figure 4C), we cannot detect any differences in Bmi-1
were genotyped using 5-TGGCCTGGAGACGCAATGA-3 (senseRNA comparing PU.1/ and PU.1/ HSC by real-time
primer) and 5-CGCAGAGATTGTGCGTCTTT-3 (antisense primer),
quantitative PCR assays (H.I., B.M.O., and D.G.T., un- which gave rise to a 269 bp band for the loxP targeted allele and a
published data). 235 bp band for the wt allele, respectively (Figure 1A). To analyze
excision efficiency, genomic DNAs were digested with BamHI and
probed with the 875 bp PstI-XbaI fragment described above (FigureRelevance of These Findings to AML
1A). The excised allele generated a 4.7 kb band whereas the nonex-Given the importance of loss of C/EBP function in hu-
cised but targeted allele generated a 10.9 kb band. To induce exci-
man myeloid leukemias (Tenen, 2003), we asked whether sion of C/EBPF/F, day 2 newborn mice were given a single intraperi-
loss of C/EBP function in the adult would lead to the toneal injection of 500 g poly I:C in a volume of 50 l of PBS, or
alternatively adult mice received 450 g per injection every otherdevelopment of leukemia.WhereasC/EBP induceddif-
day for a total of seven injections (Mikkola et al., 2003).ferentiation block, and enhanced HSC repopulating ac-
tivitymay cooperate to inducea persistent accumulation
Western Blot Analysisof myeloblasts in the bone marrow (Figure 5), these
Single cell suspensions were harvested from liver and bone marrow
effects are not sufficient for development of AML. 1 month after poly I:C induction, lysed with modified RIPA buffer,
Whereas it is possible that the anemia and thromobocy- and 50 g whole-cell lysate separated on 10% SDS-PAGE gels.
topenia characteristic of human AML is not frequently Immunoblots were stained with rabbit polyclonal anti-C/EBP anti-
body (Santa Cruz), stripped, and then stained with monoclonal anti-observed in murine models due to utilization of the
murine -actin antibody (Sigma).spleen as a hematopoietic organ, we did not observe
malignant infiltration of other tissues. Furthermore, we
Flow Cytometry and Cell Sortingdid not observe the development of frank leukemia in
HSC and progenitors were isolated from fetal liver cells and mouse
mice that had been transplanted with either C/EBP/ bone marrow cells as described previously (Akashi et al., 2000;
fetal liverHSC (Figure 4) or adult C/EBP/bonemarrow Kondo et al., 1997). For analysis of peripheral blood, white blood
(Figure 5), in which the animals have survived for over cells were separated from red blood cells through dextran sedimen-
tation followed by lysis of residual red blood cells and stained with1 year in the presence of neutrophils contributed by
anti-CD45 (Ly5.2) and lineage specific markers. For single-cell clo-cotransplanted Ly5.1 C/EBP/ donor HSC. Thus, al-
nogenic assays, cells were deposited into 96-well plates after athough we cannot exclude the possibility of develop-
second round of sorting as described (Akashi et al., 2000).
ment of leukemia beyond this observation period (up to
1 year), our results suggest that additional genetic Clonogenic Assay to Determine Differentiation Potential
events will be required for final leukemic transformation. of Fetal Liver Progenitors
Myeloid progenitors were cultured in Methocult H4100 methylcellu-Accordingly, by crossing conditionally targeted C/EBP
lose media (Stemcell Technologies) with cytokines including murinemice to other strains with specific gene disruptions, as
SCF, IL-3, IL-11, TPO, and eythropoietin. Single cells were depositedwell as insertional mutagenesis, we are attempting to
into 96-well plates as described above. Colonies were enumeratedidentify the specific genetic pathways resulting in leuke-
under an inverted microscope consecutively from days 4–7.
mic transformation.
Induction of Disruption of C/EBPF/F GMP by Transduction
Experimental Procedures with a Retrovirus Expressing Cre Recombinase
To induce a disruption of C/EBP at the GMP stage, we used an
C/EBP Nonconditional Knockout Mice MSCV based retrovirus encoding the Cre recombinase followed by
C/EBP nonconditional / mice were bred and genotyped by an IRES and EGFP. GMPs were isolated from C/EBPF/F bone mar-
Southern blot analysis as previously described (Zhang et al., 1997). row and cultured with virus supernatant for 48 hr in the presence
Mice utilized in these studies were backcrossed at least six gen- of SCF and IL-11. Average transduction efficiency of GMPwas 30%.
erations in a purebred C57BL/6 background. No difference in After transduction, cells were isolated into EGFP and EGFP popu-
C/EBP/ fetal liver hematopoiesis was noted compared to the lations and assessed for recombination by PCR using the set de-
129  C57BL/6 background used in our previous studies (Zhang et scribed for genotyping C/EBPF/ mice (see sequences above) for
al., 1997). the C/EBPF allele and 5-GCCTGGTAAGCCTAGCAATCCT-3 and
5-TGGAAACTTGGGTTGGGTGT-3 for the C/EBP allele.
Generation of Loxp-C/EBP Mice
The 5 homologous genomic region in the targeting vector was a Transplantation Experiments
For transplantation of total fetal liver hematopoietic cells (Table 2),7 kb EcoRI genomic fragment encompassing the single C/EBP
exon and extending 3.3 kb upstream. A NotI-loxP-NotI linker (38 bp) 6- to 8-week-old recipients (Ly5.1 C57BL/6) were irradiated with
550 rads followed by a 4 hr interval and then a second dose of 400was inserted into a NotI site located 600 bp upstream of the C/EBP
exon. The 3 homologous region was isolated from a 1.6 kb 3 rads of 
 irradiation from a 137Cs source. 2  106 total fetal liver
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hematopoietic cells from day 14.5 gestation Ly5.2 C57BL/6 Duprez, E.A., Koch, H., Wagner, K., and Tenen, D.G. (2003). C/EBP:
a major PML/RARA responsive gene mediating granulopoiesis inC/EBP/or C/EBP/micewere used asdonor cells. Reconstitu-
tion by donor cells was detected by staining peripheral white blood retinoic acid-induced APL cell differentiation. EMBO J. 22, 5806–
5816.cells with anti-CD45.2 (Ly5.2) antibody. Progenitors populations
were analyzed 6 to 9 months after transplantation. Gombart, A.F., Hofmann, W.K., Kawano, S., Takeuchi, S., Krug, U.,
For transplantation of purified fetal liver HSC, KSL fetal liver cells Kwok, S.W., Larson, R.J., Asou, H., Miller, C.W., Hoelzer, D., and
from day 14.5 gestation Ly5.2 C/EBP/ or Ly5.2 C/EBP/ Koeffler, H.P. (2002). Mutations in the gene encoding the transcrip-
embryos and from Ly5.1 C/EBP/mice were isolated and a total tion factor CCAAT/enhancer binding protein  in myelodysplastic
of 200 HSCs were injected by tail vein injection into each irradiated syndromes and acute myeloid leukemias. Blood 99, 1332–1340.
Ly5.1 recipient. Donor origin cells were detected by flow cytometry
Hall, M.A., Curtis, D.J., Metcalf, D., Elefanty, A.G., Sourris, K., Robb,analyses performed every 2 weeks between 2 and 6 months after
L., Gothert, J.R., Jane, S.M., and Begley, C.G. (2003). The criticaltransplantation. For secondary transplantation, 2  106 total bone
regulator of embryonic hematopoiesis, SCL, is vital in the adult formarrow cells were harvested from mice 7.5 months after primary
megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12.transplantation and injected into Ly5.1 C57BL/6 mice irradiated
Proc. Natl. Acad. Sci. USA 100, 992–997.with a total dose of 950 rads as described above. The percentage of
Heath, V., Suh, H.C., Holman, M., Renn, K., Gooya, J.M., Parkin, S.,donor-derived cells was measured in peripheral blood as described.
Klarmann, K.D., Ortiz, M., Johnson, P., and Keller, J.R. (2004).For transplantation of adult total bone marrow cells (Figure 5),
C/EBP deficiency results in hyperproliferation of hematopoieticLy5.1 recipients were irradiated with a total of 950 rads. 2  105
progenitor cells and disrupts macrophage development in vitro andtotal bone marrow cells were harvested from Ly5.2 Mx1-Cre 
in vivo. Blood 104, 1639–1647.C/EBPF/F or C/EBPF/F mice and mixed with Ly5.1 C57BL/6 bone
marrow cells in the ratios indicated in Figure 5A. Reconstitution of Higuchi, M., O’Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.J., and
Ly5.2 cellswasmonitored at 1 and 2.5months after transplantation, Downing, J.R. (2002). Expression of a conditional AML1/ETO onco-
followed by administration of poly I:C (450 g/mouse every other gene bypasses embryonic lethality and establishes a murine model
day for a total of seven injections) 2.5months after transplant. Recip- of human t(8;21) acute myeloid leukemia. Cancer Cell 1, 75–87.
ientmicewere sacrificed and donor derivedbonemarrowprogenitor
Ichikawa, H., Asaka, T., Saito, T., Seo, S., Yamamoto, G., Yamagata,populations analyzed 6 months after poly I:C administration.
T., Yamazaki, I., Kurokawa, M., Mitani, K., and Hirai, H. (2002). AML1
is required for megakaryocytic maturation in adult hematopoiesis.
Quantitative Real-Time PCR Assay of HoxB4 and Bmi-1
Blood 100, 130a.
RNA in C/EBP/ HSC
Iwama, A., Zhang, P., Darlington, G.J., McKercher, S.R., Maki, R.A.,2000 to 5000 KSL HSCs were isolated by FACS and then resorted
and Tenen, D.G. (1998). Use of RDA analysis of knockout mice todirectly into 500 l trireagent. RNA was reverse transcribed and
identify myeloid genes regulated in vivo by PU.1 and C/EBP. Nu-subsequently amplified with an AbiPrism 7700 Sequence Detector
cleic Acids Res. 26, 3034–3043.by the following parameters: 48C (30 min), 95C (10 min), followed
by 40 cycles of 95C (15 s), and 60C (60 s). For Bmi-1, the forward Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H.,
primer was 5-CCAGCAAGTATTGTCCTATTTGTGA-3, the reverse Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., et al. (2004). En-
primerwas 5-ATATCTTGAAGAGTTTTATCTGACCTTATGTT-3, and hanced self-renewal of hematopoietic stem cells mediated by the
the probe was 5-FAM-TCCAGGTTCACAAAACCAGACCACTCCT- polycomb gene product Bmi-1. Immunity 21, this issue, 843–851.
TAMRA-3. For measurement of HoxB4 RNA, the forward primer Johansen, L.M., Iwama, A., Lodie, T.A., Sasaki, K., Felsher, D.W.,
was 5-CCTGGATGCGCAAAGTTCA-3, the reverse primer was 5- Golub, T.R., and Tenen, D.G. (2001). C-myc is a critical target for
CGTCAGGTAGCGGTTGTAGTGA-3, and the probe was 5-FAM- C/EBP in granulopoiesis. Mol. Cell. Biol. 21, 3789–3806.
TGAGCACGGTAAACCCCAATTACGCC-TAMRA-3.
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